These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 7530821

  • 1. Correlation between objective nasal mucosal swelling and estimated stuffiness during long-term use of vasoconstrictors.
    Graf P, Juto JE.
    ORL J Otorhinolaryngol Relat Spec; 1994; 56(6):334-9. PubMed ID: 7530821
    [Abstract] [Full Text] [Related]

  • 2. One-week use of oxymetazoline nasal spray in patients with rhinitis medicamentosa 1 year after treatment.
    Graf P, Hallén H.
    ORL J Otorhinolaryngol Relat Spec; 1997; 59(1):39-44. PubMed ID: 9104748
    [Abstract] [Full Text] [Related]

  • 3. Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity.
    Graf P.
    Rhinology; 1996 Mar; 34(1):9-13. PubMed ID: 8739860
    [Abstract] [Full Text] [Related]

  • 4. Effect on the nasal mucosa of long-term treatment with oxymetazoline, benzalkonium chloride, and placebo nasal sprays.
    Graf P, Hallén H.
    Laryngoscope; 1996 May; 106(5 Pt 1):605-9. PubMed ID: 8628089
    [Abstract] [Full Text] [Related]

  • 5. Clinical and rhinostereometric assessment of nasal mucosal swelling during histamine challenge.
    Graf P, Hallén H.
    Clin Otolaryngol Allied Sci; 1996 Feb; 21(1):72-5. PubMed ID: 8674227
    [Abstract] [Full Text] [Related]

  • 6. One year follow-up of patients with rhinitis medicamentosa after vasoconstrictor withdrawal.
    Graf PM, Hallén H.
    Am J Rhinol; 1997 Feb; 11(1):67-72. PubMed ID: 9065350
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Decongestion effect and rebound swelling of the nasal mucosa during 4-week use of oxymetazoline.
    Graf P, Juto JE.
    ORL J Otorhinolaryngol Relat Spec; 1994 Feb; 56(3):157-60. PubMed ID: 7515487
    [Abstract] [Full Text] [Related]

  • 9. Sustained use of xylometazoline nasal spray shortens the decongestive response and induces rebound swelling.
    Graf P, Juto JE.
    Rhinology; 1995 Mar; 33(1):14-7. PubMed ID: 7540314
    [Abstract] [Full Text] [Related]

  • 10. Four-week use of oxymetazoline nasal spray (Nezeril) once daily at night induces rebound swelling and nasal hyperreactivity.
    Graf P, Hallén H, Juto JE.
    Acta Otolaryngol; 1995 Jan; 115(1):71-5. PubMed ID: 7762389
    [Abstract] [Full Text] [Related]

  • 11. [Ultrastructural changes in human nasal mucosa in rhinitis medicamentosa].
    Knipping S, Holzhausen HJ, Riederer A, Bloching M.
    HNO; 2006 Oct; 54(10):742-8. PubMed ID: 16477462
    [Abstract] [Full Text] [Related]

  • 12. Benzalkonium chloride in nasal decongestive sprays has a long-lasting adverse effect on the nasal mucosa of healthy volunteers.
    Hallén H, Graf P.
    Clin Exp Allergy; 1995 May; 25(5):401-5. PubMed ID: 7553242
    [Abstract] [Full Text] [Related]

  • 13. Extended use of topical nasal decongestants.
    Yoo JK, Seikaly H, Calhoun KH.
    Laryngoscope; 1997 Jan; 107(1):40-3. PubMed ID: 9001263
    [Abstract] [Full Text] [Related]

  • 14. Ten days' use of oxymetazoline nasal spray with or without benzalkonium chloride in patients with vasomotor rhinitis.
    Graf P, Enerdal J, Hallén H.
    Arch Otolaryngol Head Neck Surg; 1999 Oct; 125(10):1128-32. PubMed ID: 10522506
    [Abstract] [Full Text] [Related]

  • 15. An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion.
    Morris S, Eccles R, Martez SJ, Riker DK, Witek TJ.
    Am J Rhinol; 1997 Oct; 11(2):109-15. PubMed ID: 9129752
    [Abstract] [Full Text] [Related]

  • 16. Histamine sensitivity in the nasal mucosa during four-week use of oxymetazoline.
    Graf P, Juto JE.
    Rhinology; 1994 Sep; 32(3):123-6. PubMed ID: 7839081
    [Abstract] [Full Text] [Related]

  • 17. Fluticasone propionate nasal spray is more effective and has a faster onset of action than placebo in treatment of rhinitis medicamentosa.
    Hallén H, Enerdal J, Graf P.
    Clin Exp Allergy; 1997 May; 27(5):552-8. PubMed ID: 9179430
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.